ESR1 and breast cancer: Because progesterone binding to the progesterone receptors (PRs), like estrogen binding to ERs, is growth stimulatory for breast cancer cells, using antagonists to both receptors to block tumor growth may be an attractive treatment option for ER+ and PR+ breast cancers.